134 related articles for article (PubMed ID: 15269050)
1. Impact of fusion of indium-111 capromab pendetide volume data sets with those from MRI or CT in patients with recurrent prostate cancer.
Schettino CJ; Kramer EL; Noz ME; Taneja S; Padmanabhan P; Lepor H
AJR Am J Roentgenol; 2004 Aug; 183(2):519-24. PubMed ID: 15269050
[TBL] [Abstract][Full Text] [Related]
2. Improved performance of SPECT-CT In-111 capromab pendetide by correlation with diffusion-weighted magnetic resonance imaging for identifying metastatic pelvic lymphadenopathy in prostate cancer.
Hardie AD; Rieter WJ; Bradshaw ML; Gordon LL; Young MA; Keane TE
World J Urol; 2013 Dec; 31(6):1327-32. PubMed ID: 23595605
[TBL] [Abstract][Full Text] [Related]
3. Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy.
Raj GV; Partin AW; Polascik TJ
Cancer; 2002 Feb; 94(4):987-96. PubMed ID: 11920467
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up of 111In-capromab pendetide (ProstaScint) scan as pretreatment assessment in patients who undergo salvage radiotherapy for rising prostate-specific antigen after radical prostatectomy for prostate cancer.
Nagda SN; Mohideen N; Lo SS; Khan U; Dillehay G; Wagner R; Campbell S; Flanigan R
Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):834-40. PubMed ID: 17293236
[TBL] [Abstract][Full Text] [Related]
5. Ten-year outcomes: the clinical utility of single photon emission computed tomography/computed tomography capromab pendetide (Prostascint) in a cohort diagnosed with localized prostate cancer.
Ellis RJ; Kaminsky DA; Zhou EH; Fu P; Chen WD; Brelin A; Faulhaber PF; Bodner D
Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):29-34. PubMed ID: 20961696
[TBL] [Abstract][Full Text] [Related]
6. Utilization of (111)In-Capromab pendetide SPECT-CT for detecting seminal vesicle invasion with recurrent prostate cancer after primary in situ therapy.
Kimura M; Tsivian M; Mouraviev V; Mayes JM; Price MM; Bannister MC; Madden JF; Wong TZ; Polascik TJ
Int J Urol; 2009 Dec; 16(12):971-5. PubMed ID: 19843189
[TBL] [Abstract][Full Text] [Related]
7. Progress in SPECT/CT imaging of prostate cancer.
Seo Y; Franc BL; Hawkins RA; Wong KH; Hasegawa BH
Technol Cancer Res Treat; 2006 Aug; 5(4):329-36. PubMed ID: 16866563
[TBL] [Abstract][Full Text] [Related]
8. Detection of recurrent prostate carcinoma with anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT.
Schuster DM; Savir-Baruch B; Nieh PT; Master VA; Halkar RK; Rossi PJ; Lewis MM; Nye JA; Yu W; Bowman FD; Goodman MM
Radiology; 2011 Jun; 259(3):852-61. PubMed ID: 21493787
[TBL] [Abstract][Full Text] [Related]
9. Capromab Pendetide imaging of prostate cancer.
Haseman MK; Rosenthal SA; Polascik TJ
Cancer Biother Radiopharm; 2000 Apr; 15(2):131-40. PubMed ID: 10803318
[TBL] [Abstract][Full Text] [Related]
10. Procedure for unmasking localization information from ProstaScint scans for prostate radiation therapy treatment planning.
DeWyngaert JK; Noz ME; Ellerin B; Kramer EL; Maguire GQ; Zeleznik MP
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):654-62. PubMed ID: 15380603
[TBL] [Abstract][Full Text] [Related]
11. 11C-acetate positron emission tomography imaging and image fusion with computed tomography and magnetic resonance imaging in patients with recurrent prostate cancer.
Wachter S; Tomek S; Kurtaran A; Wachter-Gerstner N; Djavan B; Becherer A; Mitterhauser M; Dobrozemsky G; Li S; Pötter R; Dudczak R; Kletter K
J Clin Oncol; 2006 Jun; 24(16):2513-9. PubMed ID: 16636343
[TBL] [Abstract][Full Text] [Related]
12. Biochemical disease-free survival rates following definitive low-dose-rate prostate brachytherapy with dose escalation to biologic target volumes identified with SPECT/CT capromab pendetide.
Ellis RJ; Zhou H; Kim EY; Fu P; Kaminsky DA; Sodee B; Colussi V; Vance WZ; Spirnak JP; Kim C; Resnick MI
Brachytherapy; 2007; 6(1):16-25. PubMed ID: 17284381
[TBL] [Abstract][Full Text] [Related]
13. 111-In-capromab pendetide imaging using hybrid-γ camera-computer tomography technology is not reliable in detecting seminal vesicle invasion in patients with prostate cancer.
Tsivian M; Wright T; Price M; Mouraviev V; Madden JF; Kimura M; Wong T; Polascik TJ
Urol Oncol; 2012; 30(2):150-4. PubMed ID: 20189846
[TBL] [Abstract][Full Text] [Related]
14. Using vascular structure for CT-SPECT registration in the pelvis.
Hamilton RJ; Blend MJ; Pelizzari CA; Milliken BD; Vijayakumar S
J Nucl Med; 1999 Feb; 40(2):347-51. PubMed ID: 10025845
[TBL] [Abstract][Full Text] [Related]
15. Single photon emission computerized tomography with capromab pendetide plus computerized tomography image set co-registration independently predicts biochemical failure.
Ellis RJ; Zhou EH; Fu P; Kaminsky DA; Sodee DB; Faulhaber PF; Bodner D; Resnick MI
J Urol; 2008 May; 179(5):1768-73; discussion 1773-4. PubMed ID: 18343445
[TBL] [Abstract][Full Text] [Related]
16. Indium-111 capromab pendetide in the management of recurrent prostate cancer.
Manyak MJ
Expert Rev Anticancer Ther; 2008 Feb; 8(2):175-81. PubMed ID: 18279057
[TBL] [Abstract][Full Text] [Related]
17. Correction of photon attenuation and collimator response for a body-contouring SPECT/CT imaging system.
Seo Y; Wong KH; Sun M; Franc BL; Hawkins RA; Hasegawa BH
J Nucl Med; 2005 May; 46(5):868-77. PubMed ID: 15872362
[TBL] [Abstract][Full Text] [Related]
18. Use of local (111)in-capromab pendetide scan results to predict outcome after salvage radiotherapy for prostate cancer.
Koontz BF; Mouraviev V; Johnson JL; Mayes J; Chen SH; Wong TZ; Anscher MS; Sun L; Moul J; Polascik TJ
Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):358-61. PubMed ID: 18164863
[TBL] [Abstract][Full Text] [Related]
19. The role of 111indium-capromab pendetide imaging for assessing biochemical failure after radical prostatectomy.
Wilkinson S; Chodak G
J Urol; 2004 Jul; 172(1):133-6. PubMed ID: 15201753
[TBL] [Abstract][Full Text] [Related]
20. Multimodal and three-dimensional imaging of prostate cancer.
Lee Z; Sodee DB; Resnick M; Maclennan GT
Comput Med Imaging Graph; 2005 Sep; 29(6):477-86. PubMed ID: 15893911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]